Five months into the U.S. launch of Bristol Myers Squibb’s (BMS) Sotyktu (deucravacitinib) for psoriatic arthritis (PsA), rheumatologists are increasingly adding the oral TYK2 inhibitor to their ...

Austin, July 16, 2025 (GLOBE NEWSWIRE) -- Psoriatic Arthritis Treatment Market Size & Growth Analysis: According to SNS Insider, the global Psoriatic Arthritis Treatment Market was valued at USD 11.08 ...

NPF begins a global push to unearth and address the remaining milestones on the path to a cure for psoriasis and ...

For most people with psoriatic arthritis, the availability of highly effective therapies means that the goal of treatment is a score-based outcome known as minimal disease activity (MDA). But many ...

If you're one of the millions of people dealing with psoriatic arthritis, you know just how frustrating it can be. One day, you're moving just fine and the next, you're hit with joint pain, stiffness ...

EXTON, PA, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Since the first US FDA-approved tumor necrosis factor (TNF) inhibitor in 2002 for the treatment of psoriatic arthritis (PsA), TNF's have upheld their ...

Trinity Health posted a 1.1% operating margin on $26.8 billion in FY2026 while cutting 557 IT jobs and shifting hospital assets. What patients should know. Bradford, Pennsylvania, Residents Face ...

—In a study of more than 600 psoriatic arthritis (PsA) patients conducted in a real-world setting, investigators recently sought to identify phenotype clusters and how they’re associated with patients ...

or on the link below. Participants in the Psoriatic Arthritis Research Consortium completed standardized assessments, including patient-reported outcome (PROs) instruments, between 2017 and 2020.

Psoriatic arthritis (PsA) is a chronic inflammatory arthritis which appears in around one-third of people with psoriasis. EULAR—The European Alliance of Associations for Rheumatology—is committed to ...

Some people with psoriatic arthritis (PsA) may have a disease that is difficult to manage (D2M) or does not respond to treatment. EULAR—The European Alliance of Associations for Rheumatology—has ...

Failure to respond to targeted disease-modifying antirheumatic drugs (tsDMARDs) for psoriatic arthritis occurs at an incident rate of about 0.35 per person-year. An observational cohort of 591 ...